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Abstract
BACKGROUND: The diagnostic efficacy of 18F-FDG-PET imaging in brain tumors is markedly reduced due to high glucose me-
tabolism in normal brain tissue. This requires further research for more sensitive and specific tracers. 18F-fluoroethylo-L-thyrosine 
(18F-FET) is an interesting PET radiotracer, which shows promising results in patients with brain tumors. The aim of this study was 
to compare 18F-fluoroethylo-L-thyrosine PET/CT and MRI in the diagnosis of primary brain tumors referred to radiation therapy.
MATERIAL AND METHODS: Thirteen patients (5M, 8F) with mean age of 56y ± 13 and histologically confirmed primary brain 
tumors were investigated. The MRI scans were performed on MRI 1.5T scanner with FSE, DWI method, T1, T2 and FLAIR se-
quence. The examination was performed using brain protocol for 35 minutes and prior to PET imaging. The PET scans were 
performed 20–40 min after intravenous injection of 160 MBq of 18F-FET. Scans were acquired on Gemini TF PET/CT scanner 
using 3D brain imaging protocol for 10 minutes acquisition time. The reconstructed PET images were evaluated on a dedicated 
EBW workstation with Time-of-Flight reconstruction algorithms. On reconstructed images, the tumor borders were drawn using 
dedicated software, based on various threshold values and tumor borders and volumes were calculated on each nuclear image 
and compared with the volume calculated on the diagnostic MRI. For statistical analysis the t-test was used. 
RESULTS: 18F-FET-PET imaging in total showed more abnormal lesions that MRI; however, the difference was not significant 
(p > 0.05). There were two patients with lesions detected only on the MRI study and 4 patients with abnormal tracer uptake 
within the brain in 18F-FET study with no correlation in the MRI study. 18F-FET-PET method showed 30 lesions in 11 patients 
with mean SUVmax value of 2.33 (range from 1.6 to 3.5). Based on 70% threshold cutoff value, the mean volume of brain focus 
was calculated on at 31.15 ± 26.89 mm3 and was in concordance with mean lesion volume measured on the MRI scan 31.51 
± 34.97 mm3. For radiation planning purposes other threshold values, as well as gradient based methods were evaluated on 
18F-FET-PET imaging.
CONCLUSION: PET/CT imaging with 18F-fluoroethylo-L-thyrosine is complementary to MRI in the diagnosis of primary brain 
tumors referred to radiation therapy.
KEY words: radiotherapy, brain tumor, positron emission tomography, 18F-fluoroethylo-L-thyrosine, magnetic 
resonance
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Introduction 
The most commonly used non-invasive methods of brain 
imaging include computed tomography (CT) and magnetic 
resonance (MR) which allow assessment of anatomical struc-
tures and are characterized by high sensitivity. The limitation in 
the application of these imaging methods are changes caused by 
the applied treatment (e.g. surgery, radiation-induced necrosis). 
In such cases, the nuclear medicine techniques, in particular 
positron emission tomography in combination with computed 
tomography (PET/CT) are helpful. The radiotracer most commonly 
used in the imaging of tumor metabolism is 2-deoxy-2-[18F]
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fluoro-D-glucose (18F-FDG). It has been demonstrated that 
there is a relationship between histopathological diagnosis and 
18F-FDG uptake: high-grade tumors show hypermetabolism, 
while low-grade tumors — hypometabolism compared to gray 
matter. Low-grade astrocytomas had low 18F-FDG uptake, while 
astrocytomas and glioblastoma multiforme are characterized by 
increased uptake [1–3]. Due to high glucose uptake in healthy 
brain tissue, more sensitive and specific radiotracers are used in 
brain tumors imaging. 
18F-fluoroethylo-L-thyrosine (18F-FET) is an artificial amino 
acid showing increased uptake within malignant lesions and also 
allowing good differentiation in both high and low-differentiated 
tumors [4]. Differences in uptake of 18F-FDG and 18F-FET in primary 
brain tumor are shown in Figure 1.
The aim of this study was to compare 18F-fluoroethylo-L-thy-
rosine PET/CT and MRI in the diagnosis of primary brain tumors re-
ferred to radiation therapy.
Material and methods 
Retrospective analysis was performed on a group of 13 pa-
tients (5M, 8F), with mean age of 56 ± 13y (range 35–77yrs) and 
histologically confirmed primary brain tumors. Eleven of these 
patients had craniotomies prior to the study, 2 were without any sur-
gical intervention. The study has been approved by the Institutional 
Bioethical Committee and all subjects signed an informed consent 
form. All patients were qualified for radiotherapy treatment and tu-
mors were located in frontal, parietal, temporal and occipital lobes.
The MRI scans were performed on MRI 1.5T scanner using the 
brain protocol for 35 minutes, with the FSE method in transverse, 
sagittal and frontal planes, T1- and T2 dependent time, FLAIR se-
quences and DWI, with intravenous administration of the contrast 
agent. The PET scans were performed 20–40 min after intrave-
nous injection of 160 MBq of 18F-fluoroethylo-L-thyrosine on Gemini 
TF PET/CT scanner (Philips) using 3D brain imaging protocol for 
10 minutes acquisition time. The reconstructed PET images were 
evaluated on a dedicated EBW workstation with time-of-flight (TOF) 
reconstruction algorithms. On reconstructed images, using semi-
automatic dedicated software based on various threshold values, 
tumor borders and volume were calculated on each nuclear image 
and compared with the volume calculated on the diagnostic MRI. 
A 70% cutoff method was used to compare PET and MR images. 
All standardized uptake values (SUVs) used at work are maximum 
values (SUVmax). For statistical analysis the T-test was used.
Results 
The 18F-FET-PET study showed more lesions in the brain area than 
the MRI study; however, the difference was not statistically significant 
(p > 0.05). There were two patients whose lesions were detected only 
in MRI, and 4 patients in whom PET imaging with tyrosine showed 
increased radiotracer uptake without reference to MRI (Tab.  1). 
Table 1. Sensitivity of MRI and 18F-FET-PET imaging
No. Diagnosis MRI 18F-FET-PET
N Scan results  
(positive/negative)
N Scan results  
(positive/negative)
SUVmax.
1 Glioblastoma multiforme 1  + 0 - - 
2 Glioblastoma multiforme 1  + 1  + 1.7
3 Glioblastoma multiforme 4  + 4  + 1.9
4 Oligoastrocytoma Grade II 4  + 1  + 2.8
5 Astrocytoma Grade II 1  + 2  + 2.5
6 Oligoastrocytoma Grade II 0 - 1  + 1.6
7 Glioma Grade II 0 - 5  + 1.9
8 Astrocytoma Grade II 5  + 0 -  -
9 Astrocytoma Grade III 1  + 1  + 1.9
10 Glioblastoma multiforme 4  + 4  + 3.5
11 Oligoastrocytoma Grade II 0 - 3  + 2.7
12 Astrocytoma Grade III 4  + 4  + 2.8
13 Astrocytoma Grade III 0 - 4  + 2.3
A B
Figure 1. Differences in uptake of 18F-FDG and 18F-FET in primary 
brain tumor
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18F-FET-PET showed 30 lesions in 11 patients with an average 
SUVmax of 2.33 (range 1.6–3.5), while the MRI examination showed 
25 lesions in 9 patients.
Based on 70% cutoff, the mean volume in the 18F-FET-PET study 
was 31.15  ± 26.89 mm3 and was comparable to the volume of 
changes measured in the MRI 31.51  ± 34.97 mm3.
An example of a patient who underwent left-sided frontal 
craniotomy is showed in Figure 2. In MRI images, after intrave-
nous administration of contrast medium on the back contour of 
the post-surgical cavity, 4 fine-grained regions of up to 10 mm3 
were found, which corresponded to the resumption of the malig-
nant process. In the 18F-FET-PET study, the area of non-uniformly 
increased 18F-FET accumulation along the side and rear walls of the 
post-surgical cavity. The most active focal points are visible at the 
rear wall and at the side wall. The image suggests an active prolif-
erative process in the left frontal lobe. As another example, a patient 
after left-sided occipital craniotomy with increased 18F-FET uptake 
in the lateral part of the post-surgical cavity. In MRI hyperintensive 
area in T2-weighted images caused by previous treatment which 
make some difficulties in interpretation of the study (Fig. 3). 
An important aspect is the size of the observed lesions in this two 
studies. In both methods, the formula for the volume of the ellipse 
was used to assess the volume (V = 4/3*π*a*b*c). In the case 
of 7 lesions, the volumes in MRI were higher than in 18F-FET-PET, 
while in 9 lesions volumes were higher in 18F-FET-PET than MRI. 
The mean of all lesions detected in the MRI (25) was 44.70 mm3 
while in the 18F-FET-PET (30) study it was 25.28 mm3. However, the 
differences were not statistically significant (p > 0.05).
Discussion
Many authors point to the difficulty in differentiating the 
recurrence of the tumor from postoperative edema, occurring 
in the area of the post-surgical cavity. Using the PET imaging 
with18F-fluoroethylo-L-thyrosine does not cause such a problem, 
because this radiotracer accumulates only in the areas of active 
proliferative process. This makes it easier to distinguish a tumor 
from healthy brain tissue, changes occurs postoperatively or 
under the influence of radiotherapy. Studies have shown that the 
18F-fluoroethylo-L-thyrosine PET defines biological tumor volume 
(BTV) and reflects brain tumor tissue more accurately than MRI [5,6]. 
Other studies on a small group of patients, suggest that the post-
operative 18F-FET-PET is a prognostic factor before radiotherapy 
[7–10]. This study on PET imaging with 18F-fluoroethylo-L-thyrosine 
showed more lesions than MRI. The difference in the number of 
foci between 18F-FET-PET and MRI may result from the difficulty 
in differentiating MRI lesions caused by the recurrence of the tu-
mor, from edema occurring after the surgical treatment. Similar 
Figure 2. Patient after left-sided craniotomy. (A) MRI images, (B) CT images, (C) 18F-FET-PET images
Figure 3. Patient after left-sided occipital craniotomy. (A) MRI images, (B) CT images, (C) 18F-FET-PET images
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studies were conducted by Grosu et al. where they compared 
18F-fluoroethylo-L-thyrosine-based biological tumor volume for 
radiotherapy planning in high-grade glioma with conventional 
MRI–based gross tumor volume. They found that biological tumor 
volume and gross tumor volume were different in size and localiza-
tion in two thirds of the patients [11]. 
Because of specificity of 18F-fluoroethylo-L-thyrosine 
which does not accumulate in inflammatory and reactive tis-
sues, imaging with this agent is more accurate in detection 
of tumor recurrence and gives a better definition of target vol-
umes prior to radiotherapy [12–13]. Kläsner et al. performed 
a study on a group of 25 patients where they investigated the 
value of early post-operative 18F-FET-PET to assess the resection 
status in comparison to intra-operative findings, as well as MRI. 
They reported complete resection in 12 out of 25 (48%), in 6 out of 
25 cases (24%) incomplete resection and in 7 patients 18F-FET-PET 
showed discordant findings [14]. In our limited study, in 85% PET 
showed positive scans results, while MRI only in 70%.
The major limitation of this study is a small group of patients and 
because of that the statistical analysis for sensitivity and specific-
ity was not performed. However even in spite of this, the study 
showed a comparable value of 18F-FET-PET/CT and MRI in the 
assessment of primary brain tumors. As a consequence of these 
observations 18F-FET-PET/MR should be considered as a method 
which provides better disease status evaluation of primary brain 
tumor. Another important limitation of this study is that not all le-
sions detected in both methods were verified by histopathological 
examination, so false positive findings could not be excluded.
Conclusions
18F-FET-PET/CT and MRI play complementary roles in the 
diagnosis of primary brain tumors referred to radiation therapy.
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